scholarly article | Q13442814 |
P50 | author | Sara K. Vesely | Q47704315 |
Deirdra R Terrell | Q56477350 | ||
Brian Curtis | Q68181804 | ||
P2093 | author name string | James N George | |
Richard H Aster | |||
Daniel W Bougie | |||
Jessica A Reese | |||
P2860 | cites work | Quinine-induced disseminated intravascular coagulation | Q28334464 |
Cocaine-induced acute renal failure, hemolysis, and thrombocytopenia mimicking thrombotic thrombocytopenic purpura | Q28378388 | ||
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): A case report | Q33329687 | ||
Occult quinine-induced thrombocytopenia | Q33335490 | ||
Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen | Q33337591 | ||
Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes | Q33340232 | ||
Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action | Q33344074 | ||
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients | Q33346954 | ||
Quinine induced HUS-TTP: an unusual presentation | Q33358133 | ||
Quinine/quinidine-induced thrombocytopenia: a great imitator | Q33358724 | ||
Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. | Q33389987 | ||
Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012. | Q33405202 | ||
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features | Q33408146 | ||
Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases | Q33413338 | ||
Syndromes of thrombotic microangiopathy | Q33417044 | ||
Drug-induced thrombotic microangiopathy: a systematic review of published reports | Q33418784 | ||
Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature | Q33491281 | ||
Drug-induced thrombocytopenia: a systematic review of published case reports | Q33504761 | ||
Adverse drug reactions: definitions, diagnosis, and management | Q40739350 | ||
Thrombotic microangiopathy associated with gemcitabine: rare but real. | Q45978337 | ||
Drug-induced immune thrombocytopenia | Q80768388 | ||
P433 | issue | 5 | |
P921 | main subject | Oklahoma | Q1649 |
P304 | page(s) | 406-410 | |
P577 | publication date | 2015-02-25 | |
P1433 | published in | American Journal of Hematology | Q4744246 |
P1476 | title | Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin | |
P478 | volume | 90 |
Q96304836 | An Update in Drug-Induced Thrombotic Microangiopathy |
Q33705135 | Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab |
Q33431057 | Carfilzomib: A cause of drug associated thrombotic microangiopathy |
Q58727886 | Complement-mediated thrombotic microangiopathy associated with lupus nephritis |
Q33429589 | Diversity and severity of adverse reactions to quinine: A systematic review |
Q58704884 | Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol |
Q58805821 | Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians |
Q98292974 | Drug-Induced Thrombotic Microangiopathy Resulting in ESRD |
Q64907238 | Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib. |
Q92134406 | Eculizumab in chemotherapy-induced thrombotic microangiopathy |
Q46032407 | Effective treatment of chemotherapy induced atypical Haemolytic Uraemic Syndrome: a case series of 7 treated patients. |
Q30276550 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue |
Q89373702 | Haemolytic uraemic syndrome |
Q41070320 | Hemolytic anemia |
Q48299809 | Ixazomib-induced thrombotic microangiopathy. |
Q92924160 | Late Presentation of Carfilzomib Associated Thrombotic Microangiopathy |
Q47841893 | Long-term outcomes of health-related quality of life following diverse thrombotic microangiopathy syndromes. |
Q50224262 | Neurological variability in chemotherapy-induced posterior reversible encephalopathy syndrome associated with thrombotic microangiopathy: Case reports and literature review |
Q64933058 | Prasugrel and Acquired Thrombotic Thrombocytopenic Purpura Associated with ADAMTS13 Activity Deficiency. |
Q33432949 | Proteasome inhibitor associated thrombotic microangiopathy |
Q26739684 | Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting |
Q90601264 | Thrombotic Thrombocytopenic Purpura Associated with Pazopanib |
Q41247102 | Thrombotic microangiopathy associated with Valproic acid toxicity |
Q42368351 | Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. |
Q55346941 | Thrombotic thrombocytopenic purpura possibly triggered by Graves' disease. |